Retina

During a presentation at the EURETINA 2021 Virtual Congress, Dr Anat Loewenstein discussed how artificial intelligence can optimize optical coherence tomography.

During a presentation at the EURETINA 2021 Virtual Congress, Dr José-Alain Sahel explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.

Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.

Prof Carel B. Hoyng discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

Professor Quan Dong Nguyen speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Dr Chekitaan Singh discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.

Speaking during the EURETINA 2021 Virtual Congress, Dr Marta Belmonte-Grau discussed the potential risk for posterior capsular rupture during cataract surgery.

In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.

Integration of spectral domain optical coherence tomography with ultra-wide field imaging can increase accurate detection of diabetic macular oedema and epiretinal membrane.

Results may represent a retinal degenerative change.

Fluorescence lifetime imaging ophthalmoscopy may be useful to monitor the progression of AMD as well as the effectiveness of treatment approaches.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

Long-term treatment helps chronic, vision-threatening disease.

Ophthalmologists face challenges of drug delivery for retinal diseases.

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.

With at least 24 inherited retinal disease (IRD) clinical trials ongoing in the United States, and additional studies of stem cell therapy in several IRD indications, hope is on the horizon for many patients.

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Types of delivery methods currently being explored to improve treatment for patients with retinal disorders.

Why investigators are recognising AMD as a disease spectrum rather than a single entity.

The proportion of eyes that developed PDR or centre-involving DMO was lower with periodic aflibercept treatments compared with sham treatment through the 2-year point.

Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.

Challenges associated with delivering therapies currently available to treat retinal disorders and methods being explored to improve drug delivery to patients.

Drawbacks and challenges associated with the administration of anti-VEGF injections currently available to treat retinal diseases.

Dr Mariya Moosajee highlights therapies approved as well as under study to improve treatment for patients with inherited retinal disease.

A discussion regarding the roles of various treatments available for diabetic macular edema and considerations for selecting and sequencing therapy.

An overview of the current treatment landscape for age-related macular degeneration and factors that impact treatment selection.